Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
June 28, 2021NEW YORK, June 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. to Participate in Industry and Investor Conferences in June
June 10, 2021NEW YORK, June 10, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
June 1, 2021NEW YORK, June 1, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…BEAT-COV Endorses Initiative of the German Government for EUR 300 Million Funding Program for Late-Stage COVID-19 Therapies (in German Only)
May 17, 2021BEAT-COV begrüßt Initiative des Bundes für 300 Millionen Euro Förderprogramm für versorgungsnahe COVID-19-Medikamente Deutschland, 17. Mai 2021 – Das Bundesministerium…Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
May 6, 2021– EMPhASISCohort 2Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting…Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838’s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
April 15, 2021– Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Combination with Existing 30…Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
April 13, 2021NEW YORK, April 13, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
March 31, 2021NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective…Immunic, Inc. to Participate in Industry and Investor Conferences in March
March 2, 2021NEW YORK, March 2, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
February 26, 2021– Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021– –…